EBITDA

The value furniture giant is going public, revealing strong growth and ambitious expansion plans. Can its "Everyday Low Prices" model win over Wall Street?

With a new $1.6B valuation led by T. Rowe Price, Hadrian is scaling its AI-powered factories to spearhead America's industrial and defense resurgence.

Amid rising regulatory pressure, dxFeed's flawless performance in a critical industry-wide disaster recovery test sets a new benchmark for data reliability.

With promising data in hard-to-treat cancers, iOnctura's lead drug, roginolisib, is set to make waves at the top healthcare investment forum.

With a key FDA decision looming, Orca Bio's massive new funding aims to commercialize a therapy that could make curative transplants safer for more patients.

Rigetti Computing pushes back its Cepheus-1-108Q launch to Q1 2026, a move that rattled investors but underscores the quantum industry's tough race for fidelity.

Koppers Holdings navigates a key leadership change as CFO Jimmi Sue Smith retires. Veteran Bradley Pearce takes the helm as interim financial chief.

The fintech platform grew twice as fast as the overall market in 2025, fueled by tech innovation and a surge in multi-protocol trading adoption.

A validated study on LEON's FR-JET® mixer shows it creates highly concentrated, potent mRNA nanoparticles, promising to speed up drug development.

Private equity giant Bain Capital and BlueWater Marinas acquire Kent Narrows Boatel, signaling a new wave of investment in the luxury boating market.

The Oncology Institute promotes new CIO and CPO, signaling a strategic push into AI-driven care and robust talent management to dominate the market.

With $82M in funding and novel gene insertion technology, Averna Therapeutics is poised to make waves at the pivotal J.P. Morgan Healthcare Conference.

With record revenue and a bold AI strategy, Opera heads to a key investor conference. Can its 'agentic' browsers redefine the web and win market share?

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.

Facing complex 2025 tax changes? H&R Block is offering new DIY clients a free professional review, blending digital convenience with expert assurance.

An expanded partnership aims to create next-gen cancer therapies by combining bispecific antibodies with two distinct drugs to overcome tumor resistance.

Major insurers now cover advanced AI plaque analysis, paving the way for personalized heart attack prevention and a new standard of cardiovascular care.

The biotech firm now expects Phase 2 results in Q3 2026, accelerating hope for new CNS treatments and signaling strong operational momentum to investors.

Predis.ai's new AI promises to slash video ad costs and production time, empowering small businesses and challenging traditional marketing workflows.

A massive 20-year pact between Meta and Vistra will revive three nuclear plants, adding new carbon-free power to fuel the AI and data center revolution.